Kaynak: Zacks Investment Research Haber Ajansı
1 ay önce•
Hisse Senedi Orta Önem
Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Falls

Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Falls

OCGN posts a wider Q2 loss as R&D spending climbs, while advancing late-stage gene therapy programs and extending its cash runway into 2028.
İlgili Semboller 1
OCGN OCGN
Kaynak: Zacks Investment Research
Kaynağı Ziyaret Et
0 0 0
Yorum Yap
Yorumlar
0
Henüz yorum yok
Bu habere ilk yorum yapan kişi olun.